Drugs Information:
Tazemetostat
Basic Information
|
|
||
| ID | DDInter1750 | |
| Drug Type | small molecule | |
| Molecular Formula | C34H44N4O4 | |
| Molecular Weight | 572.750 | |
| CAS Number | 1403254-99-8 | |
| Description | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.[L11476] Tazemetostat was first named in literature as EPZ-6438.[A190363] Tazemetaostat was granted FDA approval on 23 January 2020.[L11476] | |
| ATC Classification | L01XX72 | |
| IUPAC Name | N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-5-[ethyl(oxan-4-yl)amino]-4-methyl-4'-[(morpholin-4-yl)methyl]-[1,1'-biphenyl]-3-carboxamide | |
| InChI | NSQSAUGJQHDYNO-UHFFFAOYSA-N | |
| Canonical SMILES | CCN(C1CCOCC1)C1=C(C)C(=CC(=C1)C1=CC=C(CN2CCOCC2)C=C1)C(=O)NCC1=C(C)C=C(C)NC1=O | |
| Useful Links | DrugBank PubChem Substance ChemSpider BindingDB Wikipedia ChEMBL ZINC | |
Interactions with
Tazemetostat
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|